

Brentuximab vedotin : アドセトリス®

（カナダ及び米国は除く）

- Studies which evaluate reversibility of peripheral neuropathy

Brigatinib : アルンブリグ®

- Studies investigating brigatinib in NSCLC, evaluation of CNS activity, rational combinations with other agents/modalities, and sequencing of ALK TKIs

Cabozantinib : カボメティクス®

（日本のみ）

- Studies following solid tumor refractory to standard-of-care (SOC) therapy
- Studies exploring predictors of efficacy and to assess novel combination therapies for renal cell carcinoma
- Studies of side effect management

Fruquintinib

（中華人民共和国、香港、マカオを除く）

- Combination studies with fruquintinib in metastatic colorectal cancer (mCRC), utilizing agents with a clear scientific rationale
- Descriptions of the observed effectiveness and tolerability of fruquintinib in CRC in the clinic population and/or identification of subgroups who may derive the most benefit from the therapy
- Generation of observational data characterizing treatment patterns, safety, and outcomes for patients with refractory mCRC to identify optimal sequencing of agents/mechanisms of action (MOAs)

Ixazomib : ニンラー□[®]

- Currently not accepting proposals

Niraparib : ゼジューラ®

（日本、韓国、台湾のみ）

- Studies on overcoming resistance to PARP inhibitors and platinum-based chemotherapy
- Studies on improving adherence and promoting the appropriate use
- Studies exploring predictive factors or investigating novel combination therapies for ovarian cancer and PARP inhibitors
- Studies investigating novel treatment therapy after refractory to standard-of-care (SOC) therapy in solid tumors

Panitumumab : ベクティビックス®

（日本のみ）

- Currently not accepting proposals